NASDAQ: CRVSCorvus Pharmaceuticals Inc Stock Ownership - Who owns Corvus Pharmaceuticals?
Insider buying vs selling
Have Corvus Pharmaceuticals Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Orbimed Advisors LLC | Director | 2025-06-27 | 1,397,684 | $3.50 | $4.89MBuy |
| Orbimed Advisors LLC | Director | 2025-06-27 | 1,176,332 | $4.16 | $4.89MSell |
| Peter A. Thompson | Director | 2025-06-27 | 1,397,684 | $3.50 | $4.89MBuy |
| Peter A. Thompson | Director | 2025-06-27 | 1,176,332 | $4.16 | $4.89MSell |
| William Benton Jones | SVP Pharmaceutical Development | 2025-06-04 | 19,357 | $3.50 | $67.75kBuy |
| Richard A. Md Miller | President and CEO | 2025-05-07 | 559,073 | $3.50 | $1.96MBuy |
CRVS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when CRVS insiders and whales buy or sell their stock.
CRVS Shareholders
What type of owners hold Corvus Pharmaceuticals Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Orbimed Advisors LLC | 9.59% | 7,165,006 | $63.84M | Institution |
| Peter A. Thompson | 9.59% | 7,165,006 | $63.84M | Insider |
| Orbimed Advisors LLC | 9.59% | 7,165,006 | $63.84M | Insider |
| Point72 Asset Management LP | 8.64% | 6,454,274 | $57.51M | Institution |
| Ecor1 Capital LLC | 6.91% | 5,162,154 | $45.99M | Insider |
| Blackrock Inc | 6.31% | 4,710,442 | $41.97M | Institution |
| Vanguard Group Inc | 4.65% | 3,471,925 | $30.93M | Institution |
| Terry P. Gould | 4.56% | 3,402,422 | $30.32M | Insider |
| Adams Street Partners LLC | 4.56% | 3,402,422 | $30.32M | Insider |
| Adams Street Partners LLC | 4.39% | 3,275,616 | $29.19M | Institution |
CRVS vs Biotech Stocks
Corvus Pharmaceuticals Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.